A Metabolomics Approach To Identify Metabolites Associated with Uremic Symptoms in Patients Receiving Maintenance Hemodialysis
Authors:
- Solaf Al AwadhiSASolaf Al Awadhi
- Leslie MyintLMLeslie Myint
- Eliseo GuallarEGEliseo Guallar
- Clary B. ClishCCClary B. Clish
- Kendra E. WulczynKWKendra E. Wulczyn
- Sahir KalimSKSahir Kalim
- Dorry L. SegevDSDorry L. Segev
- Mara McAdams-DeMarcoMMMara McAdams-DeMarco
- Sharon M. MoeSMSharon M. Moe
- Jonathan HimmelfarbJHJonathan Himmelfarb
Open Access
- 23 September 2025
- journal article
- Published by Wolters Kluwer Health in Kidney360
- Vol. 7 (2) , 353-361
Abstract
Key Points: Uremic symptoms are common in patients with kidney failure, but the chemicals causing them are unknown. We used state-of-the-art untargeted metabolomics and rigorous analyses to search for metabolites associated with uremic symptoms. We identified metabolite-symptom associations but could not replicate findings and offer recommendations for future research. Background: The specific toxins causing uremic symptoms (nausea, vomiting, pruritus, fatigue, difficulty concentrating, and pain) in kidney failure remain unknown. We used untargeted metabolomics to identify plasma metabolites associated with uremic symptoms in patients receiving hemodialysis. Methods: We measured metabolites in plasma samples from Longitudinal US/Canada Incident Dialysis study participants at baseline (discovery; n =636) and year 1 (internal validation; n =260) and from Frailty Assessment in Renal Disease study participants (external validation; n =355). We used metabolite-wise linear models with empirical Bayesian inference to evaluate the association between metabolites and uremic symptom severity, adjusting for key covariates. We accounted for multiple testing using a false discovery rate ( P values adjusted for false discovery rate [pFDR]) for linear models and used two machine learning models to evaluate the association consistency. We defined association as significant if pFDR < 0.1 and consistent if it had medium or high importance in both machine learning models. Results: Participants had a mean age of 63 years, with uremic symptom prevalence ranging from 44% to 83%. We identified 627 previously characterized (known) and 35,558 unknown metabolite peaks. No known metabolites were significantly and consistently associated with uremic symptom severity across all cohorts. Within cohorts, retinol was negatively associated with nausea/vomiting in Longitudinal US/Canada Incident Dialysis at year 1, and indole-3-propionic acid was negatively associated with anorexia in Frailty Assessment in Renal Disease. Several unknown metabolites were associated with symptoms (lowest pFDR, 0.0004), but none were consistent across cohorts. Conclusions: We identified metabolites associated with uremic symptom severity, although findings were inconsistent across cohorts. This study highlights the need for additional research on uremic toxins and clinical outcomes.Keywords
Funding Information
- National Institute of Nursing Research (R01NR017399)
- National Institute of Nursing Research (R01NR017399)
This publication has 35 references indexed in Scilit:
- Normal and Pathologic Concentrations of Uremic ToxinsJournal of the American Society of Nephrology, 2012
- MissForest—non-parametric missing value imputation for mixed-type dataBioinformatics, 2011
- Sleep disorders, depressive symptoms and health-related quality of life--a cross-sectional comparison between kidney transplant recipients and waitlisted patients on maintenance dialysisNephrology Dialysis Transplantation, 2010
- The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational StudiesPLOS Medicine, 2007
- Evaluation of Effect of Renal Transplantation in Treatment of Restless Legs SyndromeTransplantation Proceedings, 2007
- Restless legs syndrome in patients after renal transplantationAmerican Journal of Kidney Diseases, 2005
- Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray ExperimentsStatistical Applications in Genetics and Molecular Biology, 2004
- Stimulation of Lipid Peroxidation in Vitro in Rat Brain by the Metabolites Accumulating in Maple Syrup Urine DiseaseMetabolic Brain Disease, 2002
- Uremic Toxicity: Urea and BeyondSeminars in Dialysis, 2001
- On the mechanisms of the formation of L-alloisoleucine and the 2-hydroxy-3-methylvaleric acid stereoisomers from L-isoleucine in maple syrup urine disease patients and in normal humans.Journal of Biological Chemistry, 1992